Beyond glucose in type 2 diabetes: how Novo Nordisk is looking to address chronic kidney disease

After moving from academia to industry, Stephen Gough is now Novo Nordisk’s global chief medical officer, working on putting patients at the centre of the company and providing medical leadership to its R&D strategy, as well as seeking out pre-competitive partnerships. We speak to him about the company’s drive to tackle the complications of type 2 diabetes, such as chronic kidney disease, and how they see the future unfolding with GLP-1 agonists and beyond.